Sign In
Buy XOMA
$41.70
+0.0100 (+0.0240%)
At Close: Jun 03, 2026
XOMA Declares Quarterly Preferred Stock Dividends
07:30am, Thursday, 21'st Mar 2024
EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash divide
EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biop
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital
XOMA to Present at Upcoming Investor Conferences in March
07:30am, Wednesday, 28'th Feb 2024
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following M
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biop
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash p
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
08:30am, Thursday, 18'th Jan 2024
XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Dep
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of Ju
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
07:30am, Monday, 08'th Jan 2024
EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive O
XOMA Announces Stock Repurchase Program of up to $50 Million
07:30am, Tuesday, 02'nd Jan 2024
XOMA to repurchase up to $50M of its stock before January 2027. Management actively participating in capital structure to maximize shareholder value.
XOMA Declares Quarterly Preferred Stock Dividends
07:30am, Wednesday, 20'th Dec 2023
EMERYVILLE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividen
Low-cost financing capitalizes on XOMA's $14 million acquisition of VABYSMO® (faricimab) royalties in 2021
I'm Buying Preferred Stocks Hand Over Fist
08:30am, Friday, 15'th Dec 2023
Preferred shares present a desirable trifecta of high yields, lower risk, and significant capital upside. At these bargain prices, preferred stocks have something for value, income, and growth investo
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
02:18pm, Monday, 18'th Sep 2023
Xoma (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
